ZE74-0282 not checked

Eilean Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“ZE74-0282 is an oral powder for suspension supplied in 25 mg and 75 mg sachets. It is administered orally with noncarbonated water once daily (QD) or twice daily (BID), as assigned/selected by cohort, in continuous 28-day treatment cycles. Dosing is performed in a fasting state: no food or drink other than water for at least 2 hours before and 1 hour after dosing. The starting dose is 150 mg QD.…”In the company’s words, NCT07529951 on ClinicalTrials.gov
Tested for
Polycythemia Vera (PV), Myelofibrosis (MF)
Main trialPhase 1
“This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of single, split, and multiple oral doses of ZE74-0282 under fasted or fed conditions in healthy adult volunteers.”In the company’s words, NCT07527221 on ClinicalTrials.gov

Other drugs for Polycythemia Vera (PV)

All 18 drugs for Polycythemia Vera (PV)

Coming up2

Changes1

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Nov 2026 Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Phase 1Recruiting 30 Sep 2028 Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ZE74-0282

Following is part of Solo: you see every change to ZE74-0282 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in